Literature DB >> 3281979

Comparison of six serological assays for human immunodeficiency virus antibody detection in developing countries.

P Van de Perre1, D Nzaramba, S Allen, C H Riggin, S Sprecher-Goldberger, J P Butzler.   

Abstract

Three commercially available assays for the detection of human immunodeficiency virus (HIV) antibodies-Vironostika enzyme immunoassay (EIA), Wellcozyme competitive EIA, and JLC Allaman indirect immunofluorescence assay--were tested on 300 serum samples from African subjects with and without HIV-related conditions. Two experimental assays both rapid and simple to perform (Biotech dip stick and Cambridge Bioscience latex agglutination) were also evaluated on the same serum samples. The results were compared with those of a commercial Western blot (WB) (immunoblot) assay from Biotech, used as the reference technique. All assays were tested in the laboratory of the AIDS Project in Kigali, Rwanda. Calculated specificity ranged from 90.8% (dip stick) to 98.6% (Vironostika EIA, Wellcozyme competitive EIA, and Cambridge Bioscience latex agglutination). Sensitivity ranged from 95.2% (Cambridge Bioscience latex agglutination) to 98.0% (Vironstika EIA) and JLC indirect immunofluorescence assay). However, the sensitivity of the latex agglutination test improved to 98.6% after the prozone effect was controlled for by serial twofold dilution of latex agglutination-negative, WB-positive samples. In situations with a high prevalence of HIV infection, any one of these tests can be regarded as an alternative to the more expensive, time-consuming, and difficult WB assay.

Entities:  

Keywords:  Antibodies--analysis; Biology; Cost Benefit Analysis; Developing Countries; Diseases; Equipment And Supplies; Evaluation; Evaluation Methodology; Examinations And Diagnoses; Hiv Infections; Immunity; Immunologic Factors; Laboratory Examinations And Diagnoses; Physiology; Quantitative Evaluation; Viral Diseases

Mesh:

Substances:

Year:  1988        PMID: 3281979      PMCID: PMC266330          DOI: 10.1128/jcm.26.3.552-556.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Efficacy of five enzyme immunoassays for antibody to HIV in detecting antibody to HTLV-IV.

Authors:  F Denis; G Leonard; M Mounier; A Sangare; G Gershy-Damet; J L Rey
Journal:  Lancet       Date:  1987-02-07       Impact factor: 79.321

2.  Blood donor sera with false-positive Western blot reactions to human immunodeficiency virus.

Authors:  G Biberfeld; U Bredberg-Rådén; B Böttiger; P O Putkonen; J Blomberg; P Juto; G Wadell
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

3.  Are medical injections a risk factor for HIV infection in children?

Authors:  P Lepage; P Van de Perre; M Caraël; J P Butzler
Journal:  Lancet       Date:  1986-11-08       Impact factor: 79.321

4.  HIV-I and HIV-II double infection in Central African Republic.

Authors:  F Rey; D Salaun; J L Lesbordes; S Gadelle; F Ollivier-Henry; F Barré-Sinoussi; J C Chermann; A J Georges
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

5.  Detection of antibodies to human immunodeficiency virus by latex agglutination with recombinant antigen.

Authors:  C H Riggin; G A Beltz; C H Hung; R M Thorn; D J Marciani
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

6.  Evaluation of a clinical case-definition of acquired immunodeficiency syndrome in Africa.

Authors:  R Colebunders; J M Mann; H Francis; K Bila; L Izaley; N Kakonde; K Kabasele; L Ifoto; N Nzilambi; T C Quinn
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

7.  Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast.

Authors:  F Denis; F Barin; G Gershy-Damet; J L Rey; M Lhuillier; M Mounier; G Leonard; A Sangare; A Goudeau; S M'Boup
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

8.  Rapid, easy, and economical screening test for antibodies to human immunodeficiency virus.

Authors:  J R Carlson; S C Mertens; J L Yee; M B Gardner; E J Watson-Williams; J Ghrayeb; M B Jennings; R J Biggar
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

9.  Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia.

Authors:  M Melbye; E K Njelesani; A Bayley; K Mukelabai; J K Manuwele; F J Bowa; S A Clayden; A Levin; W A Blattner; R A Weiss
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

10.  Risk factors for human immunodeficiency virus seropositivity among children 1-24 months old in Kinshasa, Zaire.

Authors:  J M Mann; H Francis; F Davachi; P Baudoux; T C Quinn; N Nzilambi; N Bosenge; R L Colebunders; P Piot; N Kabote
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

View more
  9 in total

1.  Reactivity patterns and infection status of serum samples with indeterminate Western immunoblot tests for antibody to human immunodeficiency virus type 1.

Authors:  E Ramirez; P Uribe; D Escanilla; G Sanchez; R T Espejo
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Performance and cost-effectiveness of a dual rapid assay system for screening and confirmation of human immunodeficiency virus type 1 seropositivity.

Authors:  F A Spielberg; C M Kabeya; T C Quinn; R W Ryder; N K Kifuani; J Harris; T R Bender; W L Heyward; M R Tam; K Auditore-Hargreaves
Journal:  J Clin Microbiol       Date:  1990-02       Impact factor: 5.948

3.  Specificity of new peptide immunoassays versus other immunoassays and agglutination tests for detection of HIV antibody in African sera.

Authors:  G Léonard; M Verdier; A Sangaré; J L Rey; F Denis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

4.  False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria.

Authors:  Anne F Gasasira; Grant Dorsey; Moses R Kamya; Diane Havlir; Moses Kiggundu; Philip J Rosenthal; Edwin D Charlebois
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Comparison of five commercial enzyme-linked immunosorbent assays and Western immunoblotting for human immunodeficiency virus antibody detection in serum samples from Central Africa.

Authors:  F Behets; A Disasi; R W Ryder; K Bishagara; P Piot; M Kashamuka; M Kamenga; N Nzila; M Laga; G Vercauteren
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

6.  Evaluation of the Recombigen HIV-1 Latex Agglutination Test.

Authors:  C A Starkey; B Yen-Lieberman; M R Proffitt
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

7.  Multicenter evaluation of a fully automated screening test, VIDAS HIV 1 + 2, for antibodies to human immunodeficiency virus types 1 and 2.

Authors:  J M Azevedo-Pereira; M H Lourenço; F Barin; R Cisterna; F Denis; P Moncharmont; R Grillo; M O Santos-Ferreira
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

Review 8.  The diagnosis of human immunodeficiency virus infection: progress in less than five years.

Authors:  F J Michalski
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr

9.  A systematic review to describe patterns of animal and human viral research in Rwanda.

Authors:  M Fausta Dutuze; Maurice Byukusenge; Anselme Shyaka; Rebecca C Christofferson
Journal:  Int Health       Date:  2022-06-01       Impact factor: 3.131

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.